Kaupinen Wes - 05 Feb 2026 Form 4 Insider Report for PALVELLA THERAPEUTICS, INC. (PVLA)

Reporting relationship: President and CEO, Director, 10%+ Owner
Issuer ticker: PVLA
Reported as of: 05 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Feb 2026, 16:07:18 UTC
Prior SEC filing: 10 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Kathleen A. McGowan, Attorney-in-Fact

Key filing fact

Kaupinen Wes filed Form 4 for PALVELLA THERAPEUTICS, INC. (PVLA) on 09 Feb 2026.

Key facts

This page summarizes Kaupinen Wes's Form 4 filing for PALVELLA THERAPEUTICS, INC. (PVLA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Feb 2026, 16:07.

Change

Previous filing in this sequence was filed on 10 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001918142 Primary reporting owner

Kaupinen Wes

Relationship: President and CEO, Director, 10%+ Owner
Address: C/O PALVELLA THERAPEUTICS, INC., 353 W. LANCASTER AVENUE, SUITE 200, WAYNE
Signature: /s/ Kathleen A. McGowan, Attorney-in-Fact
Signature date: 09 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PVLA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +124,603
Change %
Price: $0.000000
Shares after: 124,603
Date: 05 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 124,603
Exercise price: $76.43
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.